Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Chris Calabrese - MD, LifeSci Advisors Ted White - President & CEO Joe Bonaccorso - CCO Terry Kohler - CFO Gary Goldenberg - CMO Chris Hayes - Chief Legal Officer Conference Call Participants Stacy Ku - TD Cowen Anish Nikhanj - RBC Capital Markets Glen Santangelo - Jefferies Oren Livnat - H.C. Wainwright Serge Belanger - Needham and Company Kemp Dolliver - Brookline Capital Markets Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3137900 (State or other jur ...

Exhibit 99.1 Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results – Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – Conference ID: 13746100 International Dial-In Number: 1-201 ...

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Conference Call February 29, 2024 8:30 AM ET Company Participants Kevin Gardner - Managing Director-LifeSci Advisors Ted White - President & Chief Executive Officer Joe Bonaccorso - Chief Commercial Officer Terry Kohler - Chief Financial Officer Gary Goldenberg - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen Oren Livnat - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Good morning, ladies and gentlemen, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38529 Verrica Pharmaceuticals Inc. (State or other jurisdiction of incorporation or organization) 44 West Gay Street, Suite 400 West Chester, PA 19380 (Address of princ ...

EXHIBIT 99.1 Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast Information – Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, PA –Feb 29, 2024 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a dermatology therapeutics company deve ...

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Kevin Gardner - LifeSci Advisors Ted White - President & Chief Executive Officer\ Joe Bonaccorso - Chief Commercial Officer Terry Kohler - Chief Financial Officer Chris Hayes - Chief Legal Officer Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Serge Belanger - Needham & Co Kemp Dolliver - Brookline Capital Markets Operator Good morning, ladies and ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3137900 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in its Charter) For the transition period from to For the quarterly period ended June 30, 2023 OR Commission File Number: 001-38529 WASHINGTON, DC 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Verrica Pharmaceuticals Inc. (Mark One) Indicate by check mark whether the regis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 46-3137900 (State or other jurisdiction of incorporation or organization) 44 West Gay Street, Suite 400 West Chester, PA 19380 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) Registrant's telephone number, including area code: (484) 453-3300 N/A For the quarterly period ended Marc ...